Patient
Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts
This week, Novartis and Bristol-Myers Squibb paused several CAR-T therapy trials for autoimmune diseases due to serious safety incidents, with Novartis reporting three deaths. The news caused fluctuations in related companies' stock prices, analysts began assessing the impact, and multiple developers emphasized differences in their therapy process designs to reduce expectations of risk transmission.
FDA allows unique endpoint in rare disease study
AMO Pharma announced that the registrational trial design for its rare disease candidate drug AMO-02 has been approved by the US FDA, the UK's Medicines and Healthcare products Regulatory Agency (MHRA), and Health Canada, allowing hospitalization rate to be used as the primary efficacy endpoint. The company's CEO, Mike Snape, stated that this may be the first time regulators have permitted such an endpoint in late-stage orphan drug studies. The design aims to address the high heterogeneity of clinical manifestations in congenital myotonic dystrophy and could impact the field of rare disease drug development.
Why ivermectin is in the limelight again
Ivermectin, an antiparasitic drug approved by the FDA in 1996, became a point of contention during the COVID-19 pandemic due to unproven efficacy claims. Now, the drug has regained public attention as early laboratory and animal studies suggest it may interfere with tumor cell signaling. Although professional organizations such as the American Cancer Society warn that it is unproven and no human trials have validated it, states like Florida have already invested funds to explore its anticancer potential, and related early-stage clinical trials are underway.
Vertex’s Journavx made history, but left a void in the pain space
Although Vertex's Journavx received FDA approval and made history, its sales have fallen short of expectations, and it has not fully filled the gap for non-opioid painkillers. Companies such as Tris Pharma are developing new drugs to fill this void.
A new company rises from the ashes of Purdue Pharma
Purdue Pharma has officially dissolved after reaching a $7.4 billion nationwide settlement, and the newly established public-benefit company Knoa Pharma began operations on May 1, pledging to prioritize public health, but critics argue the settlement sets a bad precedent for industry accountability.
Can an LSD candidate do for anxiety what Spravato did for depression?
Johnson & Johnson's landmark approval of Spravato in 2019 opened the door to a new era of mental health drugs. Now, Definium Therapeutics (formerly MindMed) is advancing its LSD-based candidate drug DT120 for the treatment of generalized anxiety disorder (GAD). The company has completed two late-stage studies and, based on positive Phase 2 data—including a 78% clinical response rate and a 50% symptom remission rate after 4 weeks—expects to announce Phase 3 topline results in the coming months, with potential approval as early as next year. If successful, this would mark a major breakthrough in anxiety disorder treatment since Eli Lilly's Cymbalta was approved in 2007.
Analysis of Biotech IPO Recovery and Trump Tariff Exemption Channels
The biotech IPO market shows signs of recovery; Insilico Medicine and Astellas collaborate to explore AI research in women's health; Trump's drug tariffs have room for exemptions, with multiple pharmaceutical companies reducing rates through agreements.
RFK Jr. pushes for peptide reclassification, potentially fueling weight-loss drug gray market
Robert F. Kennedy Jr. (RFK Jr.) called on the FDA in a podcast to reclassify over a dozen synthetic peptides, allowing them to be compounded again through pharmacies. The move aims to bring supply under regulation, but experts warn it may mislead the public and fuel the gray market. The global peptide market exceeds $50 billion in annual sales, and experimental drugs are already circulating through gray channels.
Menopause Medical Revolution: High Demand, Lagging Science
In recent years, menopause has moved from behind the scenes to the forefront, with celebrities openly discussing it and telehealth startups emerging, fueling a $17 billion market. However, treatment demand far exceeds scientific support, as women's health research has long been underfunded, clinical trials lack adequate representation, and doctors face a shortage of evidence-based guidance. This article explores the challenges in the pharmaceutical industry's development of menopause drugs, the controversies and latest advances in hormone replacement therapy, and the future direction of personalized medicine.